rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Entera Bio Ltd. -

ENTX · Nasdaq

Health CareBiotechnologyLeadingGLP-1

ENTX stood above a rising 150-day average in 19 of the last 52 weekly readings, including each of the last 12 weeks. It is 49.1% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
12 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$262K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
24 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$159KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months8
Sale orders, 12 months0
Buyers · sellers5 · 0
WhoDidSharesTraded
Geno J. GermanoDirectorbought20,000at $1.309 Mar 2026filed 11 Mar 2026
Sean EllisDirectorbought10,000at $1.235 Mar 2026filed 9 Mar 2026
Steven D. RubinDirectorbought5,000at $1.4912 Feb 2026filed 17 Feb 2026
Geno J. GermanoDirectorbought20,000at $1.4910 Feb 2026filed 11 Feb 2026
Haya TaitelDirectorbought7,500at $1.4810 Feb 2026filed 11 Feb 2026
Sean EllisDirectorbought18,000at $1.249 Feb 2026filed 11 Feb 2026
Steven D. RubinDirectorbought10,000at $1.209 Feb 2026filed 11 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders24+0 on the quarter
New · exited6 · 6
Reported value$18.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Knoll Capital Management, LLCunchanged · filed 14 Aug 20265,881,879$10.4M00.0%
BVF INCnew · filed 14 Aug 20262,425,000$4.3M+2,425,000
Siren, L.L.C.new · filed 13 Aug 2026736,457$1.3M+736,457
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026368,847$653K-104,595−22.1%
Parkman Healthcare Partners LLCreduced · filed 14 Aug 2026274,497$486K-14,173−4.9%
PNC Financial Services Group, Inc.added · filed 7 Aug 2026273,031$483K+263,031+2630.3%
Seven Fleet Capital Management LPreduced · filed 17 Aug 2026191,354$339K-14,188−6.9%
HighTower Advisors, LLCadded · filed 5 Aug 202674,573$133K+37,743+102.5%
Schonfeld Strategic Advisors LLCadded · filed 14 Aug 202658,871$104K+3,648+6.6%
TWO SIGMA SECURITIES, LLCnew · filed 14 Aug 202648,593$86K+48,593
31 Mar 2023 – 30 Jun 2026
91623Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Dana Yaacov-Garbeli Company insiderChief Financial Officer · last 7 Aug 20262 · 0
Geno J. Germano Company insiderDirector · last 7 Aug 20262 · 0
Gregory Burshtein Company insiderChief of R&D · last 7 Aug 20260 · 0
Haya Taitel Company insiderDirector · last 7 Aug 20264 · 0
Hillel Galitzer Company insiderChief Operating Officer · last 7 Aug 20260 · 0
Miranda Jayne Toledano Company insiderChief Executive Officer · last 7 Aug 20265 · 0
Sean Ellis Company insiderDirector · last 7 Aug 20266 · 0
Steven D. Rubin Company insiderDirector · last 7 Aug 20262 · 0
Yonatan Malca Company insiderDirector · last 7 Aug 20261 · 0
Gerald M. Lieberman Company insiderDirector · last 1 Jan 20265 · 0
Gerald M. Ostrov Company insiderDirector · last 1 Jan 20261 · 0
Roger Garceau Company insiderDirector · last 1 Jan 20240 · 0

Same industry

MRNA ModernaLeading+154%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 20250.0%
Return on capital employedFY 2025 · to 31 Dec 2025-83.6%
Share count trendFY 2025 · to 23 Mar 20261.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.1M
Free cash flowFY 2025 · to 31 Dec 2025−$7.5M

Analyst forecasts

No analyst forecasts yet.